Related Experiment Video
Updated: Sep 11, 2025
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Evaluating the Therapeutic Effect of Dehydroepiandrosterone on Stromal Fibrosis and Endocrine Function in Patients
Erum Gul1, Shazia Sultana1, Seemi Tanvir2
1Department of Obstetrics and Gynaecology, Ziauddin University, Karachi, PAK.
Background:
Resistant ovary syndrome (ROS) is a rare form of ovarian dysfunction defined by the presence of normal ovarian follicles that fail to respond to gonadotropin stimulation. The adrenal androgen, dehydroepiandrosterone (DHEA), has been studied for its potential in improving ovarian response and reserve. This study investigated the therapeutic effects of DHEA on ovarian stromal fibrosis and hormonal parameters in ROS patients.
Methods:
A case-control study was conducted on 60 women diagnosed with ROS. Participants were designated as cases treated with DHEA (75 mg/day, 12 weeks) or controls (no supplementation), with 30 participants in each group. Transvaginal ultrasound (TVUS) assessments of ovarian volume, stromal fibrosis grade, and echotexture were performed before and after the treatment. Serum levels of anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), and estradiol (E2) were also analyzed. Statistical analysis was performed using IBM SPSS Statistics for Windows, version 26 (Released 2018; IBM Corp., Armonk, New York, United States). p < 0.05 was considered significant.
Results:
No significant differences were found between the two groups at baseline. By the end of 12th week, the DHEA group showed a significant improvement: 18 (60%) participants experienced a reduction in stromal fibrosis grade most commonly from Grade 2 to Grade 1, 21 (70%) showed an increase in their ovarian volume, and 14 (47%) had normalized stromal echo-texture. Changes in hormone levels were also observed, including a rise in AMH in 13 individuals (45%), a decrease in FSH in eight (28%), and an increase in estradiol in 10 (34%), which were greater than in the control group (p < 0.05).
Conclusion:
Supplementation with DHEA greatly improved the ovarian stromal structure and hormonal function in ROS patients. Due to its anti-fibrotic and functional benefits, DHEA may prove to be a promising adjunctive therapy in the management of the challenging ROS condition.
More Related Videos
Related Concept Videos
02:07Oogenesis
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...